Sangamo BioSciences | SGMO - Net Income


Sangamo BioSciences reported $-36.13M in Net Income for its fiscal quarter ending in June of 2024.





Net Income Change Date
Alaunos Therapeutics USD -1.01M 153K Mar/2026
Alnylam Pharmaceuticals USD 164.49M 41.5M Jun/2026
Alterity Therapeutics Limited AUD -6.3M 525.41K Dec/2025
Amgen USD 2.38B 556M Jun/2026
Bayer EUR 219M 2.54B Jun/2026
BioCryst Pharmaceuticals USD 78.4M 167.45M Jun/2026
Biogen USD 97.5M 222M Jun/2026
BioMarin Pharmaceutical USD 44.76M 60.76M Jun/2026
Cipla INR 7.89B 2.34B Jun/2026
Clal Biotechnology ILS -6.17M 15.56M Dec/2022
Compugen USD -7.67M 64.51M Mar/2026
CSL USD 401M 96.5M Dec/2025
Gilead Sciences USD -10.5B 12.52B Jun/2026
GlaxoSmithKline GBP 435M 1.3B Jun/2026
Grifols EUR 114.37M 34.03M Dec/2025
Ionis Pharmaceuticals USD -114.65M 21.65M Jun/2026
J&J USD 210M 5.32B Sep/2026
Karyopharm Therapeutics USD -22.39M 79.81M Mar/2026
Merck USD -1.34B 2.9B Jun/2026
Novartis USD 3.26B 108M Jun/2026
Omeros USD -32.23M 23.81M Sep/2024
Pfizer USD -248M 2.94B Jun/2026
Roche Holding CHF 6.87B 1.4B Jun/2026
Sangamo BioSciences USD -36.13M 12.96M Jun/2024
Sanofi EUR 343M 1.27B Jun/2026
Sarepta Therapeutics USD 330.96M 743.18M Mar/2026
Tectonic Therapeutic USD -25.24M 6.02M Mar/2026
Ultragenyx Pharmaceutical USD -185M 56M Mar/2026
Vertex Pharmaceuticals USD 1.1B 68.4M Jun/2026